Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201304108 Principal Investigator: Chapman, William
Title: A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
Phase: II Disease Site: Liver
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
This is a research study for patients who received a liver transplant and are at high risk of liver cancer recurrence after liver transplant. It is not known whether sorafenib, the study medication, is effective in preventing cancer recurrence in high risk patients following liver transplantation. The purpose of this study is to determine if sorafenib is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation.
 
More Information:
Clinicaltrials.gov Entry
Internal Protocol Documents (requires Siteman administrative database password)